Funding sources The Consensus Meeting, May 2011 was financially supported by Cephalon to include room hire and travel expenses of the group.
U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma
Article first published online: 3 DEC 2012
© 2012 The Authors. BJD © 2012 British Association of Dermatologists
British Journal of Dermatology
Volume 168, Issue 1, pages 192–200, January 2013
How to Cite
Scarisbrick, J.J., Morris, S., Azurdia, R., Illidge, T., Parry, E., Graham-Brown, R., Cowan, R., Gallop-Evans, E., Wachsmuth, R., Eagle, M., Wierzbicki, A.S., Soran, H., Whittaker, S. and Wain, E.M. (2013), U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. British Journal of Dermatology, 168: 192–200. doi: 10.1111/bjd.12042
Conflicts of interest None declared.
- Issue published online: 21 DEC 2012
- Article first published online: 3 DEC 2012
- Accepted manuscript online: 10 SEP 2012 10:48AM EST
- Accepted for publication 31 August 2012
Background Bexarotene is a synthetic retinoid from the subclass of retinoids called rexinoids which selectively activate retinoid X receptors. It has activity in cutaneous T-cell lymphoma (CTCL) and has been approved by the European Medicines Agency since 1999 for treatment of the skin manifestations of advanced-stage (IIB–IVB) CTCL in adult patients refractory to at least one systemic treatment. In vivo bexarotene produces primary hypothyroidism which may be managed with thyroxine replacement. It also affects lipid metabolism, typically resulting in raised triglycerides, which requires prophylactic lipid-modification therapy. Effects on neutrophils, glucose and liver function may also occur. These side-effects are dose dependent and may be controlled with corrective therapy or dose adjustments.
Objectives To produce a U.K. statement outlining a bexarotene dosing schedule and monitoring protocol to enable bexarotene prescribers to deliver bexarotene safely for optimal effect.
Methods Leaders from U.K. supraregional centres produced this consensus statement after a series of meetings and a review of the literature.
Results The statement outlines a bexarotene dosing schedule and monitoring protocol. This gives instructions on monitoring and treating thyroid, lipid, liver, blood count, creatine kinase, glucose and amylase abnormalities. The statement also includes algorithms for a bexarotene protocol and lipid management, which may be used in the clinical setting.
Conclusion Clinical prescribing of bexarotene for patients with CTCL requires careful monitoring to allow safe administration of bexarotene at the optimal dose.